FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers - Cancer Currents Blog

National Cancer Institute sent this bulletin at 08/04/2023 10:36 AM EDT

Having trouble viewing this email? View it as a Web page.

FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers
08/04/2023
	FDA approved enzalutamide (Xtandi) combined with talazoparib (Talzenna) for metastatic castration-resistant prostate cancer with alterations in any of 12 DNA repair genes. The drug combination, which blocks both DNA repair activities and hormones that fuel cancer growth, was more effective than the standard treatment in a large clinical trial.

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.